Enasidenib (AG-221), first IDH mutation-specific inhibitor, suppresses 2-HG production and induces cellular differentiation in primary human IDH2-mutated AML cells and xenograft mouse models [131]. Here, IDH2 is linked to acute myeloid leukemia.